Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (EW)
NYSE:EW
EW Stock Chart & Stats
Day’s Range― - ―
52-Week Range$58.93 - $95.25
Previous CloseN/A
Volume821.68K
Average Volume (3M)4.84M
Market Cap
$44.29B
Enterprise ValueN/A
Total Cash (Recent Filing)$3.98B
Total Debt (Recent Filing)$700.00M
Price to Earnings (P/E)51.3
Beta0.91
Next Earnings
Jul 24, 2025EPS Estimate
0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.64
Shares Outstanding586,600,000
10 Day Avg. Volume3,764,346
30 Day Avg. Volume4,839,256
Financial Highlights & Ratios
PEG Ratio17.38
Price to Book (P/B)4.18
Price to Sales (P/S)0.00
P/FCF Ratio143.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$80.89Price Target Upside5.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
---
Bulls Say, Bears Say
Bulls Say
FDA ApprovalFDA approval of the SAPIEN 3 platform in asymptomatic patients is expected to unlock a large commercial opportunity for Edwards Lifesciences.
Q1 PerformanceEdwards Lifesciences posted better-than-expected TAVR growth, consistent with recent survey data, and continued momentum in TMTT.
Revenue GuidanceManagement raised its FY25 TMTT revenue guidance by ~5% at the midpoint and maintained its FY25 overall company and TAVR revenue guidance ranges.
Bears Say
Competitive PressureContinued weakness in Japan due to lower procedure growth and competitive pressure is a challenge for Edwards Lifesciences.
Hospital Capacity ConstraintsHospital capacity constraints driven by emerging structural heart therapies have negatively impacted US TAVR volumes in recent quarters.
Pricing EnvironmentConcerns exist about the pricing environment for TAVR, as some competitors have been pricing at sizable discounts.
---
Ownership Overview
0.94% Insiders
23.18% Mutual Funds
1.37% Other Institutional Investors
49.14% Public Companies and
Individual Investors
EW FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was $58.93 and its highest was $95.25 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market cap is $44.29B.
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Jul 24, 2025 which is in 69 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Apr 23, 2025. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.596 by $0.044.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is 0.62.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 586,600,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of $0.64 in its last earnings report, beating expectations of $0.596. Following the earnings report the stock price went up 6.628%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Currently, no hedge funds are holding shares in EW
---
Edwards Lifesciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$80.89 (5.22% Upside)
$80.89 (5.22% Upside)
Blogger Sentiment
Bullish
EW Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 4.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $42.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.23%
12-Months-Change
Fundamentals
Return on Equity
16.73%
Trailing 12-Months
Asset Growth
33.75%
Trailing 12-Months
Company Description
Edwards Lifesciences
Edwards Lifesciences Corporation (EW) is a global leader in the science of heart valves and hemodynamic monitoring. The company specializes in developing innovative medical devices and technologies designed to treat structural heart disease and critically ill patients. Its core products include transcatheter heart valves, surgical heart valves, and critical care monitoring systems. Edwards Lifesciences operates primarily in the healthcare sector, with a focus on cardiovascular care and enhancing patient outcomes through pioneering solutions.
---
EW Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong financial performance and strategic advancements, such as significant revenue growth and successful product approvals. However, challenges in the Japan market and anticipated financial impacts from tariffs and acquisitions present potential hurdles.Read More>---
EW Net sales Breakdown
75.49% Transcatheter Aortic Valve Replacement
18.04% Surgical Structural Heart
6.47% Transcatheter Mitral and Tricuspid Therapies
---
EW Stock 12 Month Forecast
Average Price Target
$80.89
▲(5.22% Upside)
Technical Analysis
---